Onconase

Onconase

Experimental oncology
A ribonuclease derived from the oocytes of the frog Rana pipiens, which was in clinical trials for treating mesothelioma.
 
Adverse effects
Anorexia, flushing, vertigo.

Onconase®

P30 Protein Oncology A ribonuclease-like protein derived from frog–Rana pipiens–embryos, said to be effective against some CAs–eg, mesothelioma. See Unproven methods for cancer management.
References in periodicals archive ?
Mild hyperthermia predisposes tumor cells to undergo apoptosis upon treatment with onconase.
and Alfacell Corporation have entered into an exclusive licensing agreement under which Strativa has acquired the commercialization rights in the United States and its territories to ONCONASE (ranpirnase) from Alfacell.
GENESIS Pharma Announce Licensing Agreement for ONCONASE in Southeast Europe(C)2006 JeraOne - http://www.
The fusion protein consists of ONCONASE (ranpirnase) and a humanized anti-CD22 monoclonal antibody.
Alfacell's ONCONASE Receives Orphan Drug Designation from US II-58
Alfacell Corporation (Bloomfield, NJ; 973-748-8082), a leader in the research and development of ribonuclease enzymes with anti-cancer and other therapeutic proper-ties, announced the company has been issued new European Patent 837 878 that covers the amino acid sequence, method of manufacture, and a natural variant of its proprietary drug ONCONASE.
If granted, orphan drug status will entitle ONCONASE to seven years of marketing exclusivity for the UMM indication after FDA approval.
ONCONASE, the first of a new class of novel cancer drugs from Alfacell's innovative ribonuclease (RNase) technology platform, clearly meets this standard.
Krauss's work involves the creation of novel immunomodular forms suitable for specifically targeting ONCONASE to tumors.
Shogen will continue as CEO, and will focus on the continued development of ONCONASE and Alfacell's other novel ribonuclease product candidates, including those from its cadre of amphinases, for other indications, as well as advancing the company's promising research in the microRNA, siRNA, and RNAi areas.
ONCONASE improved the efficacy of radiation therapy in vivo, resulting in significantly greater delay in tumor growth.
I remain steadfast in my belief that Alfacell's technology platform is promising, and that ONCONASE has great potential as a novel, first-in-class anti-cancer agent.